Taken together, the known roles of TP53, PLCG1, SYK, and SOD1 and their interactions with multiple PPI networks of gene expression markers suggested their roles in the mediating distinct cell response to TKI treatment of CML. The gene discussed is SOD1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.